Companies › Seattle Project
2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GRT-C901 Patient-specific neoantigen cancer vaccine (viral-vectored) | – | Phase 2 | Colorectal Neoplasms | Mar 2027 |
| GRT-R902 Patient-specific neoantigen cancer vaccine boost | – | Phase 2 | Colorectal Neoplasms | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05141721 | GRT-C901 | Phase 2 | Colorectal Neoplasms | Oncology | Mar 2027 |
| NCT05141721 | GRT-R902 | Phase 2 | Colorectal Neoplasms | Oncology | Mar 2027 |
No annotated target.
–
iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.